Compare Sun Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GSK PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GSK PHARMA SUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 74.2 51.3 144.7% View Chart
P/BV x 3.2 11.6 27.4% View Chart
Dividend Yield % 0.7 1.4 49.1%  

Financials

 SUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
GSK PHARMA
Mar-19
SUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs4843,595 13.5%   
Low Rs3151,253 25.2%   
Sales per share (Unadj.) Rs136.9184.7 74.1%  
Earnings per share (Unadj.) Rs17.526.3 66.4%  
Cash flow per share (Unadj.) Rs26.029.2 89.2%  
Dividends per share (Unadj.) Rs4.0020.00 20.0%  
Dividend yield (eoy) %1.00.8 121.3%  
Book value per share (Unadj.) Rs188.7126.3 149.4%  
Shares outstanding (eoy) m2,399.26169.40 1,416.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.913.1 22.2%   
Avg P/E ratio x22.992.2 24.8%  
P/CF ratio (eoy) x15.483.1 18.5%  
Price / Book Value ratio x2.119.2 11.0%  
Dividend payout %22.976.1 30.1%   
Avg Mkt Cap Rs m958,864410,626 233.5%   
No. of employees `00017.85.0 358.0%   
Total wages/salary Rs m63,6245,372 1,184.4%   
Avg. sales/employee Rs Th18,490.66,306.7 293.2%   
Avg. wages/employee Rs Th3,582.61,083.1 330.8%   
Avg. net profit/employee Rs Th2,357.6898.0 262.5%   
INCOME DATA
Net Sales Rs m328,37531,281 1,049.8%  
Other income Rs m6,3601,023 621.6%   
Total revenues Rs m334,73532,304 1,036.2%   
Gross profit Rs m69,8986,009 1,163.2%  
Depreciation Rs m20,528486 4,223.8%   
Interest Rs m3,0276 50,455.0%   
Profit before tax Rs m52,7026,540 805.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,606287 -908.2%   
Tax Rs m8,2282,373 346.7%   
Profit after tax Rs m41,8684,454 940.0%  
Gross profit margin %21.319.2 110.8%  
Effective tax rate %15.636.3 43.0%   
Net profit margin %12.814.2 89.5%  
BALANCE SHEET DATA
Current assets Rs m316,54220,061 1,577.9%   
Current liabilities Rs m157,06414,543 1,080.0%   
Net working cap to sales %48.617.6 275.3%  
Current ratio x2.01.4 146.1%  
Inventory Days Days8857 154.2%  
Debtors Days Days10514 744.8%  
Net fixed assets Rs m243,10214,343 1,694.9%   
Share capital Rs m2,3991,694 141.6%   
"Free" reserves Rs m450,24519,704 2,285.0%   
Net worth Rs m452,64521,398 2,115.3%   
Long term debt Rs m20,2892 1,014,460.0%   
Total assets Rs m682,52539,113 1,745.0%  
Interest coverage x18.41,091.0 1.7%   
Debt to equity ratio x00 47,957.5%  
Sales to assets ratio x0.50.8 60.2%   
Return on assets %6.611.4 57.7%  
Return on equity %9.220.8 44.4%  
Return on capital %11.231.9 35.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m74,219534 13,898.6%   
Fx outflow Rs m27,9647,091 394.4%   
Net fx Rs m46,255-6,557 -705.4%   
CASH FLOW
From Operations Rs m65,5483,994 1,641.2%  
From Investments Rs m-25,888-1,433 1,806.1%  
From Financial Activity Rs m-57,151-3,584 1,594.8%  
Net Cashflow Rs m-13,857-1,023 1,354.3%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.1 10.2 50.3%  
FIIs % 23.0 23.8 96.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 15.4 53.9%  
Shareholders   133,026 102,036 130.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS